On Tuesday, TransMedics Group stock earned an upgrade to its Relative Strength (RS) Rating, from 69 to 73.
Can You Really Time The Stock Market?
This proprietary rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks often have an RS Rating north of 80 as they launch their biggest climbs. See if TransMedics Group stock can continue to rebound and hit that benchmark.
Is TransMedics Group Stock A Buy?
TransMedics Group stock is trying to complete a consolidation with a 145.50 entry. See if the medical stock can break out in heavy trade.
Earnings growth rose in the company's latest report from 100% to 163%, but revenue fell from 48% to 38%. Keep an eye out for the company's next round of numbers on or around Nov. 11.
TransMedics Group stock earns the No. 2 rank among its peers in the Medical-Products industry group. Insulet is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
